Xiaoyan Jiang

Professor

The University of British Columbia

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Cancer Biology Cancer Biology professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Xiaoyan Jiang is a faculty member at the University of British Columbia in Canada. Her research focuses on various aspects of leukemia, including the modulation of survival and cell cycle control in drug-resistant stem/progenitor cells, as well as the development of non-viral delivery systems for therapeutic siRNA. Recent publications highlight her investigations into biomarkers for predicting response to treatments in chronic myeloid leukemia and the therapeutic potential of targeting specific pathways and kinases associated with hematological malignancies.

Articles (14)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

University of Toronto

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Xiaoyan Jiang

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Identification of a PAK6-Mediated MDM2/p21 Axis That Modulates Survival and Cell Cycle Control of Drug-Resistant Stem/Progenitor Cells in Chronic Myeloid Leukemia

Lipopolymers as the Basis of Non-Viral Delivery of Therapeutic siRNA Nanoparticles in a Leukemia (MOLM-13) Model

Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia

Connie Eaves (1944–2024)

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia

The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia

Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis

Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial

Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias

p21-Activated kinases as promising therapeutic targets in hematological malignancies

Investigation of water‐insoluble hydrophobic polyethylenimines as RNAi vehicles in chronic myeloid leukemia therapy

Puncta intended: connecting the dots between autophagy and cell stress networks

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML.

Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors.

Collaborators (5)

Dixie Mager

Hasan Uludag

Connie Eaves

David JHF Knapp

Artem Babaian

Make your next move.